



(Company Registration Number: 198403368H)

Condensed interim financial statements for
The fourth quarter ended 31 December 2024 (“4Q2024”) and
twelve months ended 31 December 2024 (“12M2024”)

A Condensed interim consolidated statement of profit or loss and other comprehensive income

	Group					
	3 months ended 31/12/2024	3 months ended 31/12/2023	Increase / (Decrease)	12 months ended 31/12/2024	12 months ended 31/12/2023	Increase / (Decrease)
	S\$'000 (Unaudited)	S\$'000 (Unaudited)	%	S\$'000 (Unaudited)	S\$'000 (Audited)	%
<i>Continuing operations</i>						
Revenue	675	887	(23.9)	2,323	1,615	43.8
Cost of sales	(427)	(592)	(27.9)	(1,736)	(916)	89.5
Gross profit	248	295	(15.9)	587	699	(16.0)
Other operating income	13	-	n.m	164	84	95.2
Selling and distribution expenses	(350)	(166)	110.8	(884)	(462)	91.3
Administrative expenses	(1,559)	(773)	101.7	(3,667)	(2,809)	30.5
Other operating expenses	-	(3)	(100.0)	(15)	(16)	(6.3)
Finance costs	(16)	(25)	(36.0)	(54)	(59)	(8.5)
Loss before income tax	(1,664)	(666)	149.9	(3,869)	(2,563)	51.0
Income tax credit	-	5	(100)	4	5	(20.0)
Loss from continuing operations	(1,664)	(661)	151.6	(3,865)	(2,558)	51.1
<i>Discontinued operations</i>						
Profit from discontinued operations, net of tax	-	-	nm	-	31	nm
Total loss for the year presenting loss attributable to equity holders of the Company	(1,664)	(661)	151.7	(3,865)	(2,527)	53.0
Other comprehensive (loss)/income, net of tax:						
<i>Item that may be reclassified subsequently to profit or loss, net of tax</i>						
Exchange differences on translation of a foreign operation, net of tax	1	-	n.m	(1)	(2)	(50.0)
Total comprehensive loss, for the financial period/year	(1,663)	(661)	151.6	(3,866)	(2,529)	52.9
Total loss per share, for the period attributable to the owners of the company						
Basic (in cents)	(0.122)	(0.071)		(0.283)	(0.274)	
Diluted (in cents)	(0.122)	(0.071)		(0.283)	(0.274)	
Weighted average number of shares used in the computation of basic and diluted loss per share from continuing operations and discontinued operation ('000)						
	1,366,959	933,802		1,366,959	933,802	

A Condensed interim consolidated statement of profit or loss and other comprehensive income (Cont'd)

Loss before tax is determined after crediting/(charging) the following:

	Group					
	3 months ended 31/12/2024	3 months ended 31/12/2023	Increase / (Decrease)	12 months ended 31/12/2024	12 months ended 31/12/2023	Increase / (Decrease)
	S\$'000	S\$'000	%	S\$'000	S\$'000	%
	(Unaudited)	(Unaudited)		(Unaudited)	(Audited)	
Government grants	10	7	43	30	13	131
Liabilities written off	7	-	n.m	77	-	n.m.
Amortisation of intangible assets	1	(26)	n.m	(25)	(33)	(24)
Depreciation of plant and equipment	(27)	(33)	(21)	(115)	(146)	(22)
Depreciation of right-of-use assets	(85)	(98)	(13)	(271)	(266)	2
Employee benefits expenses	(440)	(405)	9	(2,222)	(1,765)	26

There are no material related party transactions apart from those disclosed in other information required by listing rule section.

B Condensed interim statements of financial position

	Group		Company	
	31/12/2024 S\$'000 (Unaudited)	31/12/2023 S\$'000 (Audited)	31/12/2024 S\$'000 (Unaudited)	31/12/2023 S\$'000 (Audited)
NON-CURRENT ASSETS				
Plant and equipment	191	297	35	50
Right-of-use assets	1,364	777	94	183
Investment in subsidiaries	-	-	3,720	2,650
Intangible assets	40	65	-	-
Other non-current asset	9	9	-	-
Other receivables	62	53	-	-
	1,666	1,201	3,849	2,883
CURRENT ASSETS				
Inventories	1,238	963	24	24
Trade and other receivables	1,036	869	1,006	551
Cash and cash equivalents	8	409	-*	133
	2,282	2,241	1,030	708
Total Assets	3,948	3,442	4,879	3,591
CURRENT LIABILITIES				
Lease liabilities	259	220	37	59
Deferred consideration	5	200	-	-
Trade and other payables	2,857	1,260	1,734	871
Loan and borrowings	-	500	-	500
Loan from a director	-	1,017	-	1,017
Amount due to directors	190	184	85	184
Provision for other liabilities	-	44	-	45
	3,311	3,425	1,856	2,676
NON-CURRENT LIABILITIES				
Provision for reinstatement costs	77	77	-	-
Lease liabilities	1,024	553	67	145
Deferred consideration	92	192	-	-
Loan and borrowings	899	400	807	-
Deferred tax liabilities	7	11	-	-
	2,099	1,233	874	145
Total Liabilities	5,410	4,658	2,730	2,821
Net current liabilities	(1,029)	(1,184)	(826)	(1,968)
Net (liabilities)/assets	(1,462)	(1,216)	2,149	770
EQUITY				
Share Capital	46,364	42,745	46,364	42,745
Accumulated losses	(47,944)	(44,079)	(44,215)	(41,975)
Foreign currency translation reserve	1	1	-	-
Attributable to equity holders of the Company	(1,579)	1,333	2,149	770
Non-controlling interest	117	117	-	-
Total Equity	(1,462)	1,216	2,149	770

*Less than \$1,000

Aggregate amount of Group's borrowings and debt securities:

	Group		Company	
	31/12/2024	31/12/2023	31/12/2024	31/12/2023
	S\$'000	S\$'000	S\$'000	S\$'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
<u>Unsecured</u>				
Term loan	-	400	-	-
Loans from key management personal	899	500	807	500
	<u>899</u>	<u>900</u>	<u>807</u>	<u>500</u>
<u>Disclosed as:-</u>				
Non-current	899	400	807	-
Current	-	500	-	500
	<u>899</u>	<u>900</u>	<u>807</u>	<u>500</u>

Loans from key management personnel are unsecured, non-interest-bearing, and not due to be paid within one year.

C Condensed interim statements of changes in equity

The Group	Share Capital S\$'000	Accumulated Losses S\$'000	Foreign Currency translation reserve S\$'000	Total S\$'000	Non- controlling interest S\$'000	Total equity S\$'000
2024						
Balance at 1 January 2024	42,745	(44,079)	1	(1,333)	117	(1,216)
Issuance of new ordinary shares	2,991	-	-	2,991	-	2,991
Issuance of new ordinary shares pursuant to the vesting of the awards granted under the Plan	741	-	-	741	-	741
Share issue expenses	(113)	-	-	(113)	-	(113)
Loss for the year	-	(3,865)	-	(3,865)	-	(3,866)
<u>Other comprehensive loss for the financial period</u>						
Foreign currency translation	-	-	-	-	-	-
Total comprehensive loss for the financial period	-	(3,865)	-	(3,865)	-	(3,865)
Balance at 31 December 2024	46,364	(47,944)	1	(1,579)	117	(1,462)
2023						
Balance at 1 January 2023	42,745	(41,552)	3	1,196	(70)	1,126
Loss for the financial period	-	(2,527)	-	(2,527)	-	(2,527)
<u>Other comprehensive loss for the financial period</u>						
Foreign currency translation	-	-	(2)	(2)	-	(2)
Total comprehensive loss for the financial period	-	(2,527)	(2)	(2,529)	-	(2,529)
Non-controlling interest on acquisition of a subsidiary	-	-	-	-	187	187
Balance at 31 December 2023	42,745	(44,079)	1	(1,333)	117	(1,216)

C Condensed interim statements of changes in equity (Cont'd)

The Company	Share Capital capital S\$'000	Accumulated Losses S\$'000	Total equity S\$'000
2024			
Balance at 1 January 2024	42,745	(41,974)	770
Issuance of new ordinary shares	2,991	-	2,991
Issuance of new ordinary shares pursuant to the vesting of the awards granted under the Plan	741	-	741
Share issue expenses	(113)	-	(113)
Loss for the financial period	-	(2,239)	(2,239)
Total comprehensive loss for the financial period	-	(2,239)	(2,239)
Balance at 31 December 2024	46,364	(44,214)	2,150
2023			
Balance at 1 January 2023	42,745	(41,503)	1,242
Loss for the financial period	-	(472)	(472)
Total comprehensive loss for the financial period	-	(472)	(472)
Balance at 31 December 2023	42,745	(41,975)	(770)

D Condensed interim consolidated statement of cash flows

	Group	
	12 months ended 31/12/2024	12 months ended 31/12/2023
	S\$'000	S\$'000
Cash flow from operating activities		
Loss before tax from continuing operations	(3,869)	(2,563)
Profit before tax from discontinued operation	-	30
	(3,869)	(2,533)
<u>Adjustments for:</u>		
Depreciation of plant and equipment	115	146
Depreciation of right-of-use assets	271	266
Amortisation of intangible assets	25	33
Interest expense on lease liabilities	38	45
Gain on disposal of discontinued operation	-	(106)
Gain on bargain purchase on acquisition of a subsidiary	-	(4)
(Gain)/Loss on lease modification	(1)	2
Unwinding of discount of deferred consideration	-	8
Employee Share Award	741	
Liabilities written off	(77)	
Operating loss before working capital changes	(2,757)	(2,143)
<u>Changes in working capital:</u>		
Inventories	(275)	(72)
Trade and other receivables	(176)	(152)
Trade and other payables	1,387	627
Net cash used in operations	(1,821)	(1,740)
Interest paid	(38)	(45)
Net cash used in operating activities	(1,859)	(1,785)
Cash flows from investing activities		
Purchase of property, plant and equipment	(9)	(3)
Proceeds from disposal of a subsidiary, net of cash disposed	-	244
Acquisition of a subsidiary, net of cash acquired	-	130
Net cash (used in)/generated from investing activities	(9)	371
Cash flows from financing activities		
Payment of principal portion of lease liabilities	(347)	(246)
Amount due to director	-	191
Proceeds from loan from a director, net of repayment	499	1,017
Proceeds from loan and borrowings	-	693
Issuance of new ordinary shares, net of share issue expenses	1,315	-
Net cash generated from financing activities	1,467	1,655
Net (decrease)/increase in cash and cash equivalents	(401)	241
Cash and cash equivalents at beginning of financial year	409	170
Effect of currency translation on cash and cash equivalents	-	(2)
Cash and cash equivalents at end of the financial period	8	409

1. Corporate information

AJJ Medtech Holdings Limited (formerly known as OEL (Holdings) Limited) (the “**Company**”) (Registration No. 198403368H) is incorporated and domiciled in Singapore as a limited liability company and is listed on the Catalist Board of the Singapore Exchange Securities Trading Limited (“**SGX-ST**”).

The registered office and principal place of business of the Company is located at 8 Commonwealth Lane, #02-04 Grande Building, Singapore 149555.

The condensed interim consolidated financial statements as at and for the twelve months period ended 31 December 2024 comprise the Company and its subsidiaries (collectively known as the “**Group**”).

The principal activities of the Group are investment holding and the provision of integrated medtech solutions to healthcare facilities. The principal activities of the subsidiaries are:

- (a) Investment holding of healthcare technologies and services;
- (b) Provide supply chain solutions to public health institutes, including advanced medical devices and equipment, advanced medical technology development including digital solutions, and technology development;
- (c) Conduct research and development of medical technologies, manufacture and repair of irradiation and electromedical devices such as HIFU machines and other medical equipment;
- (d) Development of and distribution of:
 - (i) devices and equipment for use in the healthcare and medical industries that are primarily driven by, or enhanced or integrated with, digital tools, artificial intelligence (AI), and robotics and other medical technologies;
 - (ii) systems, solutions and applications (in software form or otherwise) that are based on or driven by digital tools, AI, robotics and other medical technologies that may be used in the healthcare and medical industries; and
- (e) Childcare wellness enhancement education material.

2. Basis of preparation

The condensed interim consolidated financial statements of the Group and the statement of financial position and statement of changes in equity of the Company for the twelve months ended 31 December 2024 have been prepared in accordance with Singapore Financial Reporting Standards (International) (“**SFRS(I)**”) 1-34 Interim Financial Reporting issued by the Accounting Standards Council Singapore. The condensed interim financial statements do not include all the information required for a complete set of financial statements. However, selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s financial position and performance of the Group since the last interim financial statements for the period ended 31 December 2024.

The accounting policies adopted are consistent with those of the previous financial year which were prepared in accordance with SFRS(I)s, except for the adoption of new and amended standards as set out in Note 2.1.

The financial statements are presented in Singapore Dollars (SGD or S\$), which is the functional currency of the Company. All values are rounded to the nearest thousand (S\$’000), except when otherwise indicated.

2.1. New and amended standards adopted by the Group

A number of amendments to Standards have become applicable for the current reporting period. The Group did not have to change its accounting policies or make retrospective adjustments as a result of adopting those standards.

2.2. Use of judgements and estimates

The preparation of the condensed interim financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the disclosure of contingent liabilities at the end of each reporting period. However, uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of the asset or liability affected in the future periods.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised and in any future period affected.

Information about assumptions and estimation uncertainties that have a significant risk of resulting in material adjustment to the carrying amounts of assets and liabilities within the next interim period are included below:

i) *Impairment on investment in subsidiaries*

The recoverable amount of the investment is reviewed at the end of each reporting period to determine whether there is any indication that the investment has suffered an impairment loss. If any such indication exists, the carrying amount of the investment is determined on the basis of the net recoverable amount to determine the extent of the impairment loss.

ii) *Leases – estimating the incremental borrowing rate*

The Group cannot readily determine the interest rate implicit in the lease, therefore it uses incremental borrowing rate to measure lease liabilities. The incremental borrowing rate is the rate of interest that the Group would have to pay to borrow over a similar term, and with a similar security, the funds necessary to obtain an asset of a similar value to the right-of-use asset in a similar economic environment. The incremental borrowing rate therefore reflects what the Group ‘would have to pay’, which requires estimation when no observable rates are available or when they need to be adjusted to reflect the terms and conditions of the lease. The Group estimates the incremental borrowing rate using observable inputs (such as market interest rates) when available and is required to make certain entity-specific estimates.

iii) *Impairment assessment on non-financial assets*

An assessment is made for the reporting year whether there is any indication that the asset may be impaired. If any such indication exists, an estimate is made of the recoverable amount of the asset. The recoverable amounts of cash-generating units if applicable is measured based on the fair value less costs of disposal or value in use calculations. It is reasonably possible, based on existing knowledge, that outcomes within the next reporting year that are different from assumptions could require a material adjustment to the carrying amount of the balances affected.

iv) *Provision for Expected Credit Losses (“ECLs”) of trade and other receivables*

The Group determines the expected credit loss for trade and other receivables based on assumptions about risk of default and expected credit loss rate. The Group adopts judgement in making these assumptions and selecting inputs for computing such impairment loss, broadly based on the available customer’s historical data, like ageing analysis of the receivables, creditworthiness and the past collection history of each customer, existing market conditions and forward-looking estimates at end of each reporting date.

3. Seasonal operations

The Group’s businesses are not affected significantly by seasonal or cyclical factors during the financial period.

4. Segment information

(a) *Products and services from which reportable segments derive their revenues*

The Group operates in the following segments:

1. Childcare wellness education material;
2. Healthcare digital products;
3. Healthcare products and services; and
4. Childcare wellness education (Discontinued operation).

Segment revenue represents revenue generated from external customers. Segment results represent the profit/(loss) earned/(incurred) by each segment without allocation of interest income, finance costs and income tax expense. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.

For the purpose of monitoring segment performance and allocating resources between segments, the chief operating decision maker monitors the tangible assets and financial assets attributable to each segment.

(b) *Segment revenues and results*

<i>Group Segment revenues</i>	3 months ended			
	31/12/2024		31/12/2023	
	Revenue		Revenue	
	S\$'000	%	S\$'000	%
Healthcare digital products	-	-	-	-
Healthcare products and services	675	100.0	887	100.0
	<u>675</u>	<u>100.0</u>	<u>887</u>	<u>100.0</u>
Timing of transfer of goods or services:				
At a point in time	<u>675</u>		<u>887</u>	
<i>Group Segment revenues</i>	12 months ended			
	31/12/2024		31/12/2023	
	Revenue		Revenue	
	S\$'000	%	S\$'000	%
Healthcare digital products	3	0.1	-	-
Healthcare products and services	2,320	99.9	1,615	100.0
	<u>2,323</u>	<u>100.0</u>	<u>1,615</u>	<u>100.0</u>
Timing of transfer of goods or services:				
At a point in time	<u>2,323</u>		<u>1,615</u>	
<i>Group Segment results</i>	3 months ended			
	31/12/2024		31/12/2023	
	Results		Results	
	S\$'000	%	S\$'000	%
Corporate and childcare wellness education material	(1,075)	64.6	(420)	62.5
Healthcare digital products	-	-	(26)	3.9
Healthcare products and services	(588)	35.4	(215)	32.5
Childcare wellness education (discontinued operation)	-	-	-	-
	<u>(1,663)</u>	<u>100.0</u>	<u>(661)</u>	<u>100.0</u>

4. Segment information (Cont'd)

<i>Group Segment results</i>	12 months ended			
	31/12/2024		31/12/2023	
	Results		Results	
	S\$'000	%	S\$'000	%
Corporate and childcare wellness education material	(2,494)	64.5	(1,975)	78.2
Healthcare digital products	-	-	(26)	1.0
Healthcare products and services	(1,371)	35.5	(557)	22.0
Childcare wellness education (discontinued operation)	-	-	31	(1.2)
	<u>(3,865)</u>	<u>100.0</u>	<u>(2,527)</u>	<u>100.0</u>

The Group's revenue for the 12 months' period ended 31 December 2024 was derived from sales of healthcare products and services, and sales of childcare wellness education material, all of which operate in Singapore. There were no inter-segment sales during the periods ended 31 December 2024 and 31 December 2023.

4. Segment information (Cont'd)
(c) Segment assets and liabilities

As at 31 December 2024 and 31 December 2023, the allocation of the Group's total assets and liabilities to the reportable segments are as follows:

	Corporate and childcare wellness education material	Healthcare digital products	Healthcare products and services	Childcare wellness education (discontinued operation)	Total
	S\$'000	S\$'000	S\$'000	S\$'000	S\$'000
Group					
31 December 2024					
Assets					
Segment assets	440	-	3,508	-	3,948
Liabilities					
Segment liabilities	(2,601)	-	(2,808)	-	(5,409)
Other information					
Amortisation	-	-	(26)	-	(26)
Depreciation	(76)	-	(311)	-	(387)
Group					
31 December 2023					
Assets					
Segment assets	660	-	2,782	-	3,442
Liabilities					
Segment liabilities	(2,593)	-	(2,065)	-	(4,658)
Other information					
Amortisation	-	-	(26)	(7)	(33)
Depreciation	(88)	-	(275)	(50)	(413)
Gain on disposal of a subsidiary	-	-	-	106	106

5. Categories of financial instruments

Financial instruments as at the reporting date are as follows:

	Group		Company	
	31/12/2024	31/12/2023	31/12/2024	31/12/2023
	S\$'000	S\$'000	S\$'000	S\$'000
<u>Financial assets</u>				
<i>At amortised cost</i>				
Trade and other receivables	939	743	967	509
Cash and bank balances	8	409	-	133
	<u>947</u>	<u>1,152</u>	<u>967</u>	<u>642</u>
<u>Financial liabilities</u>				
<i>At amortised cost</i>				
Lease liabilities	1,282	773	104	204
Deferred consideration	97	392	-	-
Trade and other payables	2,813	1,142	1,733	1,371
Loan and borrowings	899	900	807	-
Loan from a director	-	1,017	-	1,017
Amount due to directors	190	184	-	184
	<u>5,282</u>	<u>4,408</u>	<u>2,729</u>	<u>2,776</u>

6. Taxation

The Group calculates the period income tax (credit)/expense using the tax rate that would be applicable to the expected total losses before tax. The major components of income tax (credit)/expense in the financial statements for the financial period ended 31 December 2024 and 31 December 2023 are as follows:

	Group	
	3 months ended	
	31/12/2024	31/12/2023
	S\$'000	S\$'000
<u>Continuing operations</u>		
Current income tax expense	-	-
Deferred tax credit relating to reversal of taxable temporary differences	-	-
Income tax credit	<u>-</u>	<u>-</u>
<u>Discontinued operations</u>		
Current income tax expense	-	-
Deferred tax credit relating to reversal of taxable temporary differences	-	-
Income tax credit	<u>-</u>	<u>-</u>

6. Taxation (Cont'd)

	Group	
	12 months ended	
	31/12/2024	31/12/2023
	S\$'000	S\$'000
<i>Continuing operations</i>		
Current income tax expense	-	-
Deferred tax credit relating to reversal of taxable temporary differences	(4)	-
Income tax credit	(4)	-
<i>Discontinued operations</i>		
Current income tax expense	-	-
Deferred tax credit relating to reversal of taxable temporary differences	-	(1)
Income tax credit	-	(1)

7. Discontinued Operation

On 12 May 2023, the Group entered into a sale and purchase agreement (“SPA”) for the sale of 100% of the shares of one of its subsidiaries, Discovery Kidz Preschool Pte. Ltd. (“DKP”) for cash consideration of S\$0.26 million. The disposal was completed on 23 June 2023.

DKP was previously not presented as discontinued operation or classified as held for sale as at 30 June 2023. Thus, the comparative consolidated statement of comprehensive income has been re-presented to show the discontinued operation separately from continuing operations.

The results of the discontinued operation are as follows:

	01/01/2024	01/01/2023
	to	to
	31/12/2024	12/05/2023
	S\$'000	S\$'000
Revenue	-	77
Cost of sales	-	-
Gross profit	-	77
Other operating income	-	27
Administrative expenses	-	(160)
Other operating expenses	-	(15)
Finance costs	-	(5)
Loss before tax	-	(76)
Tax credit	-	1
Loss for the period	-	(75)
Gain on disposal of discontinued operation	-	106
Profit from discontinued operation	-	31

8. Dividends

No interim dividend for the period ended 31 December 2024 (31 December 2023: Nil) is recommended

9. Net Asset Value

	Group		Company	
	As at 31/12/2024 Cents	As at 31/12/2023 Cents	As at 31/12/2024 Cents	As at 31/12/2023 Cents
Net asset value per ordinary share	(0.0973)	(0.1302)	0.1430	0.0825

The calculation of net asset value per ordinary share was based on 1,502,938,302 shares as at 31 December 2024 (31 December 2023: 933,802,074).

10. Share capital

	31/12/2024		31/12/2023	
	No. of shares '000	Amount S\$'000	No. of shares '000	Amount S\$'000
Beginning of the financial period/year	933,802	42,745	933,802	42,745
Issuance of new ordinary shares	427,251	2,991	-	-
Issuance of new ordinary shares pursuant to the vesting of the awards granted under the Plan	141,885	741	-	-
Share issue expenses	-	(113)	-	-
End of the financial period/year	1,502,938	46,364	933,802	42,745

The Company had on 5 March 2024, allotted and issued 427,251,570 new ordinary shares pursuant to the loan capitalisation at a price of \$0.007 per share.

The Company has an employee share performance plan (the "Plan") under which options to subscribe for the Company's ordinary shares have been granted to certain directors and employees.

The Company had on 5 March 2024 and 19 June 2024, allotted and issued 16,000,000 and 125,884,658 new ordinary shares, respectively granted under the Plan at a price of \$0.007 and \$0.005 per share respectively.

The total number of issued shares excluding treasury shares was 1,502,938,302 as at 31 December 2024 and 933,802,074 as at 31 December 2023

There were no treasury shares held as at 31 December 2024 and 31 December 2023.

There were no subsidiary holdings as at 31 December 2024 and 31 December 2023.

There were no sales, transfers, cancellations and/or use of treasury shares or subsidiary holdings as at 31 December 2024 and 31 December 2023.

11. Subsequent Event

There are no known subsequent events which have led to adjustments to this set of interim financial statements.

Other Information Required by Listing Rule Appendix 7.2

- 1. Whether the figures have been audited or reviewed and in accordance with which auditing standard or practice.**

These figures have not been audited or reviewed by the auditors.

- 2. Where the figures have been audited or reviewed, the auditors' report (including any modifications or emphasis of a matter).**

Not applicable.

- 3. If the latest financial statements are subject to an adverse opinion, qualified opinion or disclaimer of opinion, to include:**

- (a) Updates on the efforts taken to resolve each outstanding audit issue**

- (b) Confirmation from the Board that the impact of all outstanding audit issues on the financial statements have been adequately disclosed.**

This is not required for any audit issue that is a material uncertainty relating to going concern.

Not applicable. The Group and the Company have received an unmodified audit opinion in the recent audited financial statements.

- 4. A review of the performance of the group, to the extent necessary for a reasonable understanding of the group's business. It must include a discussion of the following:**

- (a) any significant factors that affected the turnover, costs, and earnings of the group for the current financial period reported on, including (where applicable) seasonal or cyclical factors; and**

REVIEW OF TURNOVER, COSTS AND EARNINGS

Continuing operations

Revenue

The Group's revenue decreased by S\$0.21 million, from S\$0.89 million for the 3-month period ended 31 December 2023 ("4Q2023") to approximately S\$0.68 million for the 3-month period ended 31 December 2024 ("4Q2024"). In 12M2024, the Group's revenue increased by approximately S\$0.71 million to S\$2.32 million as compared to 12M2023. This increase can be primarily attributed to the improved performance of the Group's segments of healthcare digital products and healthcare products and services. The growth stems from increased demand for the Group's products and services within the healthcare sector, driven by factors such as market expansion, product innovation, and strategic partnerships.

Gross profit

Our current cost structure is elevated as part of a strategic entry into all government pharmacies across Singapore, aimed at providing essential healthcare products at an affordable price. This initial investment in equipment distribution is foundational, as it builds a reliable, long-term base of users who will later drive recurring revenue through consumables, which have stronger profit margins. This approach not only aligns with our commitment to providing accessible healthcare but also positions us for sustainable profitability as consumable sales scale up in the future.

Other operating income

The Group's operating income for 4Q2024 increased by S\$13,000 compared to 4Q2023. In 12M2024, the Group's operating income increased by S\$80,000 to S\$164,000 as compared to 12M2023. These consist of government grant, liabilities written off and reversal of accruals.

Selling and distribution expenses

Selling and distribution expenses increased by S\$0.19 million, from S\$0.16 million in 4Q2023 to approximately S\$0.35 million in 4Q2024. In 12M2024, the selling and distribution expenses increased by S\$0.42 million to S\$0.88 million as compared to 12M2023. The increase is primarily due to the addition of selling and distribution expenses of a new subsidiary, Quest Asia Technologies Pte Ltd, which was acquired in June 2023. This increase in expenses was in line with the growth in revenue.

Administrative expenses

Administrative expenses increased by S\$0.79 million from S\$0.77 million in 4Q2023 to S\$1.56 million in 4Q2024. In 12M2024, the administrative expenses increased by S\$0.86 million, from S\$2.81 million to S\$ 3.67 million. The increase is primarily due to the Group grant share award amounting to \$0.74 million to certain directors and employees whose contributions are essential to the long-term growth, success and development of the Group.

Finance costs

The Group's finance costs decreased by S\$9,000, from S\$25,000 in 4Q2023 to S\$16,000 in 4Q2024. In 12M2024, the Group's finance costs decreased by S\$5,000, from S\$59,000 in 12M2023 to S\$54,000 in 12M2024. These finance costs are mainly attributable to the interest expense related to the lease liabilities.

Loss for the financial period from continuing operations

As a result of the above, the Group reported a loss of S\$1.60 million in 4Q2024 as compared to a loss of S\$0.66 million in 4Q2023. In 12M2024, the Group reported a loss of S\$3.86 million as compared to a loss of S\$2.56 million in 12M2023.

Discontinued operation

As announced on 23 June 2023, the Group completed the disposal of its childcare wellness education business (the "**Disposal**") previously undertaken under its subsidiary, DKP with DKP ceasing to be a subsidiary of the Group on 12 May 2023.

The profit from discontinued operation in FY2023 of S\$0.03 million comprised of the gain on disposal of DKP of S\$0.11 million offset by the operating loss of DKP for the period from 1 January 2023 to 12 May 2023 (date of disposal) of S\$0.08 million.

- (b) any material factors that affected the cash flow, working capital, assets or liabilities of the group during the current financial period reported on.**

REVIEW OF WORKING CAPITAL, ASSETS AND LIABILITIES

Non-current assets

Non-current assets increased by S\$0.47 million, from S\$1.20 million as of 31 December 2023 to S\$1.67 million as of 31 December 2024. The increase was mainly due to the lease modification arising from the renewal of the office lease offset by depreciation for both the property, plant and equipment and right-of-use assets of which cumulatively amounted to S\$0.20 million and \$0.26 million related to new right-of-use assets recognised in 4Q2024.

Current assets

Current assets increased by S\$0.04 million from S\$2.24 million as of 31 December 2023 to approximately S\$2.28 million as of 31 December 2024. The increase was mainly due to the increase in inventories of S\$0.27 million and the increase in trade and other receivables of S\$0.17 million, offset by

a decrease in cash and cash equivalent of S\$0.40 million. These movements are in line with increases in revenue and expenses in 12M2024.

Current liabilities

Current liabilities decreased by approximately S\$0.11 million, from S\$3.43 million as of 31 December 2023 to S\$3.31 million as of 31 December 2024. The decrease is mainly due to the repayment of deferred consideration of S\$0.2 million, and loan from a director of S\$1.02 million through issuance of new ordinary shares (the “**capitalisation**”) during the financial year 2024. Details of the capitalisation can be found in announcements dated 8 January 2024, 17 January 2024, 26 February 2024 and 5 March 2024. These repayments were offset by an increase in trade and other payables of S\$1.60 million.

Non-current liabilities

Non-current liabilities increased by approximately S\$0.87 million, from S\$1.23 million as of 31 December 2023 to S\$2.10 million as of 31 December 2024. This was primarily due to an increase of S\$0.47 million in lease liabilities arising from lease modification and lease recognised in 4Q2024, offset by the repayment of deferred consideration and loan and borrowings through capitalisation in 1H2024. Details of the capitalisation can be found in announcements dated 8 January 2024, 17 January 2024, 26 February 2024 and 5 March 2024.

REVIEW OF CASH FLOW STATEMENT

Net cash used in operating activities

In 12M2024, the Group recorded a net cash outflow for operating activities of S\$1.86 million. The net operating cash outflow was mainly due to operating losses before working capital changes of S\$2.76 million, adjusted for working capital inflow of S\$0.93 million and \$0.04 million of interests paid. The working capital inflow is mainly due to (i) an increase in inventories of S\$0.28 million, (ii) an increase in trade and other receivables of S\$0.18 million and (iii) an increase in trade and other payables of S\$1.39 million.

Net cash generated from investing activities

In 12M2024, the Group recorded a net cash outflow of S\$9,000 million from investing activities, primarily driven by the acquisition of plant and equipment.

Net cash generated from financing activities

Net cash generated from financing activities of S\$1.47 million in 12M2024 arose mainly from proceeds from loans and borrowings of S\$0.50 million, proceeds from issuance of new ordinary shares, net of share issue expenses of S\$1.32 million, offset by the payment for principal portion of lease liabilities of S\$0.35 million.

5. **Where a forecast, or a prospect statement, has been previously disclosed to shareholders, any variance between it and the actual results.**

Not applicable.

6. A commentary at the date of the announcement of the significant trends and competitive conditions of the industry in which the group operates and any known factors or events that may affect the group in the next reporting period and the next 12 months.

Over the next 12 months, several significant trends and the evolving competitive landscape in the healthcare sector may impact the Company, including but not limited to:

The global healthcare industry is undergoing a digital transformation, with artificial intelligence (AI) and digital health technologies reshaping traditional healthcare models. The Company recognises the potential of these technologies in optimising healthcare services and improving operational efficiency. It remains committed to developing practical and deployable digital healthcare tools to enhance both medical and dental workflows. In collaboration with its partners, the Company has developed the On Call Diabetes Management Platform, enabling data-driven patient care optimisation, streamlined workflows, and preparation for future telemedicine integration. Additionally, the Company is exploring new digital healthcare applications to enhance diagnostic accuracy, patient monitoring, and accessibility. As the industry moves toward an integrated digital healthcare ecosystem, the Company is gradually shifting from price-driven competition to a data-driven product value model to strengthen its market position.

The demand for high-value and cost-effective healthcare solutions continues to rise, as governments and healthcare institutions seek to control medical expenses while ensuring product accessibility. Against the backdrop of increasing healthcare costs, the Company remains dedicated to providing high-quality, competitively priced medical devices and consumables, ensuring that patients can access essential healthcare services at affordable prices. By expanding its product portfolio, strengthening supply chain partnerships, and optimising sales channels, it is expected to further solidify the Company's position in government procurement, institutional supply, and direct sales markets, driving stable business growth.

Population aging and the increasing prevalence of chronic diseases, particularly in Singapore and globally, have led to a surging demand for chronic disease management tools, elderly care equipment, and accessible healthcare solutions. Non-communicable diseases such as diabetes and cardiovascular conditions remain major public health challenges, driving the need for innovative chronic disease management and elderly care solutions. The Company will continue to enhance its diabetes management portfolio, patient care consumables, and mobility support devices, while strengthening collaborations with retail pharmacies and healthcare institutions to improve market penetration and accessibility. Additionally, the Company is advancing its bedside care solutions to better address the increasing demand for home-based and institutional elderly care. Moving forward, the Company will focus on enhancing patient comfort, improving healthcare accessibility, and controlling medical costs, ensuring that elderly patients receive high-quality care.

The Company intends to leverage upon its Singaporean brand as the foundation for international expansion. Over the next 12 months, it plans to strengthen its international sales network, expand into new regional markets, and grow its customer base, diversifying its revenue streams. The Company is actively participating in regional government healthcare tenders, and forging strategic partnerships with local healthcare institutions, accelerating its global expansion while enhancing revenue stability.

Optimising supply chain management remains a key pillar in ensuring sustainable business growth. The global supply chain continues to face challenges, particularly in the logistics and raw material fluctuations of medical devices and essential medical supplies. The Company is actively improving supply chain management, reinforcing partnerships with leading manufacturers and logistics providers to ensure stable product supply and cost control. These efforts will enhance operational resilience ensuring the long-term sustainability of its relationships with healthcare institutions and distribution partners.

Sustainable development has become a critical focus for the global healthcare industry. The Company strictly adheres to SASB Medical Equipment and Supplies standards and is proactively exploring eco-friendly medical products and sustainable supply chain practices to minimise the environmental impact of healthcare activities. Additionally, the Company is strengthening its green healthcare solutions research and applications, ensuring that its business growth aligns with its social responsibility commitments.

Amid the continuous evolution of the MedTech sector, the Company will actively evaluate strategic investments, partnerships, and potential acquisitions to enhance its market competitiveness and drive long-term value creation.

The healthcare technology industry is undergoing profound transformation, driven by technological innovation, demographic shifts, and global market dynamics. Leveraging its strengths in AI, product innovation, and international collaborations, the Company continues to enhance its competitiveness in Singapore and across the region by addressing the healthcare needs of an aging population, expanding its global market presence, and optimising supply chain management. With these strategic initiatives, the Company is confident in seizing growth opportunities amid industry transformation, achieving long-term sustainable growth, and delivering value to its shareholders.

To support the initiatives mentioned, the Company is actively pursuing capital-raising strategies, including institutional funding, strategic investors, and debt financing, ensuring sustainable business expansion and financial stability. The Company will make further announcement(s) as and when there are material developments.

7. Dividend

(a) Current Financial Period Reported On

Any dividend declared for the current financial period reported on?

None.

(b) Corresponding Period of the Immediately Preceding Financial Year

Any dividend declared for the corresponding period of the immediately preceding financial year?

None.

(c) Whether the dividend is before tax, net of tax or tax-exempt?

Not applicable.

(d) Date payable

Not applicable.

(e) Books closure date

Not applicable.

8. If no dividend has been declared/recommended, a statement to that effect.

No dividend has been declared or recommended for the year ended 31 December 2024 in view that the Group is loss-making and focusing on expanding its business operations, in particular the Group's healthcare products and services segment.

9. If the group has obtained a general mandate from shareholders for IPTs, the aggregate value of such transactions as required under Rule 920(1)(a)(ii). If no IPT mandate has been obtained, a statement to that effect.

The Group has not obtained a general mandate for the IPTs from the shareholders.

10. Confirmation that the interim financial statements not false or misleading in any material aspect in pursuant to Rule 705(5) of the Listing Manual.

The Board of Directors hereby confirms that, to the best of its knowledge, nothing has come to the attention of the Board of Directors of the Company which may render the unaudited financial statements for the financial period ended 31 December 2024 to be false or misleading in any material aspect.

11. Confirmation that the issuer has procured undertakings from all its Directors and executive officers (in the format set out in Appendix 7H under Rule 720(1) of the Listing Manual).

The Company hereby confirms that it has already procured undertakings from all its Directors and executive officers in the format set out in Appendix 7H under Rule 720(1) of the Catalist Rules.

12. Disclosure of person occupying a managerial position in the issuer or any of its principal subsidiaries who is a relative of a director or chief executive officer or substantial shareholder of the issuer pursuant to Rule 704(10) in the format below. If there are no such persons, the issuer must make an appropriate negative statement.

Name	Age	Family relationship with any director, CEO or substantial shareholder	Current position and duties, and the year the position was held	Details of changes in duties and position held, if any, during the year
Zhang Yulei	38	Ms. Zhang Yulei is the daughter of Dr. Zhang Jian, the Chairman and Executive Director of the Company. She is also a substantial shareholder of the Company.	Chief Strategy Officer of the Company	Ms. Zhang Yulei has been engaged as a consultant for the company since 1 st May 2023 and was appointed as Chief Strategy Officer on 28 th August 2023.

BY ORDER OF THE BOARD

ZHAO XIN
 CHIEF EXECUTIVE OFFICER AND EXECUTIVE DIRECTOR
 28 February 2025

This announcement has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST").

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The details of the contact person for the Sponsor are:

Name: Mr. Jerry Chua, (Registered Professional, Evolve Capital Advisory Private Limited)

Address: 160 Robinson Road, SBF Center, #20-01/02, Singapore 068914

Tel: (65) 6381 6966